52446-52-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Bromoethyl)-4-(phenylmethoxy)benzene is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure allows for the creation of new drugs with specific therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(2-Bromoethyl)-4-(phenylmethoxy)benzene is utilized as a precursor in the synthesis of agrochemicals. Its chemical properties enable the production of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Material Science:
1-(2-Bromoethyl)-4-(phenylmethoxy)benzene is employed as a component in the development of new materials with specific properties. Its integration into material formulations can lead to the creation of innovative products with applications in various industries, such as electronics, coatings, and adhesives.

InChI:InChI=1/C15H15BrO/c16-11-10-13-6-8-15(9-7-13)17-12-14-4-2-1-3-5-14/h1-9H,10-12H2

Upstream product

• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 
• 100-44-7 benzyl chloride 
• 14140-15-9 4-(2-bromoethyl)phenol 
• 100-39-0 benzyl bromide 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 6547-53-1 2-[4-(benzyloxy)benzyl]acetic acid 

Downstream Products

• 549494-36-2 2-[4-(benzyloxy)phenyl]ethanethiol 
• 61439-61-0 ethyl p-[(p-benzyloxyphenethyl)amino]benzoate 
• 409107-91-1 2-[2-(4-benzyloxy-phenyl)-ethyl]-1,1-dioxo-1λ⁶-isothiazolidine-3-carboxylic acid methyl ester 
• 146465-90-9 sodium 4-benzyloxyphenethyl sulfonate 
• 1135032-50-6 1-{2-[4-(benzyloxy)phenyl]ethyl}cyclobutanol 
• 1269631-72-2 1-(4-(benzyloxy)phenethyl)-6-methoxy-3,7-bis(4-methoxyphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 
• 1310146-42-9 1-(4-(benzyloxy)phenethyl)-4-(3-tert-butoxy-2-azidophenyl)-6-methoxy-3,7-bis(4-methoxyphenyl)-1H-indole 
• 1269631-68-6 3-[4-(benzyloxy)phenethyl]-7-(tert-butoxy)-5-methoxy-1,4-bis(4-methoxyphenyl)-3,6-dihydropyrrolo[2,3-c]carbazole 
• 1310146-45-2 3-(4-hydroxyphenethyl)-3,6-dihydro-5-methoxy-1,4-bis(4-methoxyphenyl)pyrrolo[2,3-c]carbazol-7-ol 
• 1269631-70-0 Sulfuric acid 5-hydroxy-1,4-bis-(4-methoxy-phenyl)-3-{2-[4-(2,2,2-trichloro-ethoxysulfonyloxy)-phenyl]-ethyl}3,6-dihydro-pyrrolo[2,3-c]carbazol-7-yl ester 2,2,2-trichloro-ethyl ester 
• 1269631-73-3 sulfuric acid 1,4-bis-(4-hydroxy-phenyl)-2,5-dioxo-3-{2-[4-(2,2,2-trichloro-ethoxysulfonyloxy)-phenyl]-ethyl}-2,3,5,6-tetrahydro-pyrrolo[2,3-c]carbazol-7-yl ester 2,2,2-trichloro-ethyl ester 
• 80199-93-5 1-[4-(benzyloxy)phenethyl]-1H-imidazole 

Relevant academic research and scientific papers

Development of new HO-1 inhibitors by a thorough scaffold-hopping analysis

HO-1 inhibition is considered a valuable anticancer approach. In fact, up-regulation of HO-1 had been repeatedly reported in many types of human malignancies, and in these clinical cases, poor outcomes are reported. To identify novel HO-1 inhibitors suitable for drug development, a scaffold-hopping strategy calculation was utilized to design novel derivatives. Different parts of the selected molecule were analyzed and the different series of novel compounds were virtually evaluated. The calculation for the linker moiety of the classical HO-1 inhibitors structure led us to compounds 5 and 6. A synthetic pathway for the two molecules was designed and the compounds were synthesized. The biological activity revealed an HO-1 inhibition of 0.9 and 54 μM for molecules 5 and 6 respectively. This study suggested that our scaffold-hopping approach was successful and these results are ongoing for further development.

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

FUSED THIOPHENE COMPOUNDS

The present disclosure provides compounds that modulate protein function of 1 L-1β, IL-2, IL-6, TNF-α, CK1α, GSPT1, aiolos, ikaros or helios, to restore protein homeostasis, and 1 cell-cell adhesion. The disclosure provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators are provided. Uses of compounds for treatment or amelioration of diseases, disorders, or conditions associated with a protein, are also provided.

Efficient Difluoromethylation of Alcohols Using TMSCF2Br as a Unique and Practical Difluorocarbene Reagent under Mild Conditions

A general method for the efficient difluoromethylation of alcohols using commercially available TMSCF2Br (TMS=trimethylsilyl) as a unique and practical difluorocarbene source is developed. This method allows primary, secondary, and even tertiary alkyl difluoromethyl ethers to be synthesized under weakly basic or acidic conditions. The reaction mainly proceeds through the direct interaction between a neutral alcohol and difluorocarbene, which is different from the difluoromethylation of phenols. Moreover, alcohols containing other moieties that are also reactive toward difluorocarbene can be transformed divergently by using TMSCF2Br. This research not only solves the synthetic problem of difluorocarbene-mediated difluoromethylation of alcohols, it also provides new insights into the different reaction mechanisms of alcohol difluoromethylation and phenol difluoromethylation with difluorocarbene species.

RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING

This invention relates to novel compounds suitable for labeling by 18F and to the corresponding 18F labeled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).

Total synthesis of dictyodendrins A-E

A highly efficient total synthesis of dictyodendrins A-E was accomplished. The synthesis features a novel benzyne-mediated one-pot indoline formation/cross-coupling sequence for the construction of a highly substituted key indoline intermediate. Peripheral substituents were introduced onto this intermediate in a modular fashion to complete the total synthesis of dictyodendrins A-E. A benzyne-mediated one-pot indoline formation/cross-coupling sequence is used for the construction of a highly substituted common indole intermediate. The peripheral substituents were introduced using a Friedel-Crafts reaction on the indole intermediate in a modular fashion to complete the total synthesis. Copyright